Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

“China import-related tax issues won’t derail the business. They’re just noise and any fines will be small fry relative to the typical outflows from a company the size of AstraZeneca. Unlike GSK which ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...

Find insight on GSK, Novo Nordisk, tariff escalation and more in the latest Market Talks covering Health Care.

The pharmaceutical giant's revenue jumped 21 per cent last year despite growing troubles over its presence in China, where it is alleged to have not paid a $900,000 importation tax bill ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

GSK PLC (GSK) reports robust sales and profit growth, while navigating external pressures in the vaccine market and preparing for future product approvals.

Symphony Ltd (BOM:517385) reports a 49% increase in standalone top line and announces strategic measures to tackle forex losses and doubtful debts.

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

European shares saw a rise driven by healthcare giants GSK and Novo Nordisk following robust quarterly results. Novo Nordisk's strong profits from its drug Wegovy and GSK's share buyback plan boosted ...